NEW YORK — Skin cancer test developer Castle Biosciences said today that it has priced its planned initial public offering at $16 a share, the top end of the previously disclosed range.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.